- Conditions
- Clostridium Difficile Infection Recurrence
- Interventions
- FMT oral capsule, Oral Vancomycin, FMT oral placebo, Oral Vancomycin placebo
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Rochester, Minnesota + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 11,078
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Small-cell Lung Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Small Cell Carcinoma
- Interventions
- Abemaciclib,
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia
- Interventions
- carfilzomib, cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, methotrexate, cytarabine, leucovorin calcium, methylprednisolone, rituximab, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- Mehrdad Abedi, MD
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Breast Cancer
- Interventions
- Albumin-bound paclitaxel, Carboplatin, Herceptin®
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 14
- States / cities
- Long Beach, California • Stamford, Connecticut • Washington D.C., District of Columbia + 10 more
- Conditions
- Hyperkalemia
- Interventions
- Patiromer
- Drug
- Lead sponsor
- Vifor Pharma, Inc.
- Industry
- Eligibility
- 0 Years to 11 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 13
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Miami, Florida + 10 more
- Conditions
- Infections, Papillomavirus, Papillomavirus Vaccines
- Interventions
- CervarixTM, HPV investigational vaccine GSK568893A, different formulations
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 25 Years · Female only
- Enrollment
- 383 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Golden, Colorado • Salt Lake City, Utah
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric
- Interventions
- Pegaspargase, Erwinia asparaginase, Cyclophosphamide, CYTARABINE, DASATINIB, DEXAMETHASONE, Dexrazoxane, Doxorubicin, ETOPOSIDE, HYDROCORTISONE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, NELARABINE, Vincristine
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2034
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • New Brunswick, New Jersey • Buffalo, New York + 3 more
- Conditions
- Diabetes Mellitus
- Interventions
- BGP-15 100 mg QD, BGP-15 100 mg BID, Placebo BID, BGP-15 200 mg QD, BGP-15 200 mg BID, BGP-15 400 mg QD
- Drug
- Lead sponsor
- N-Gene Research Laboratories, Inc.
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Paramount, California • Tustin, California + 17 more
- Conditions
- Glioblastoma, Glioblastoma, WHO Grade IV
- Interventions
- Temozolomide (TMZ), Optune System, Pembrolizumab
- Drug · Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Food Allergy
- Interventions
- Omalizumab, Food Flour Buildup
- Drug
- Lead sponsor
- Kari Christine Nadeau
- Other
- Eligibility
- 4 Years to 55 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Mountain View, California • Chicago, Illinois + 4 more
- Conditions
- PTSD
- Interventions
- Riluzole, Placebo (for Riluzole)
- Drug
- Lead sponsor
- Uniformed Services University of the Health Sciences
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Syracuse, New York
- Conditions
- Migraine
- Interventions
- Ubrogepant, Placebo-Matching Ubrogepant
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 1,059 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 125
- States / cities
- Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 102 more
- Conditions
- Small Cell Lung Carcinoma Extensive Disease
- Interventions
- Durvalumab, Tremelimumab, Carboplatin, Cisplatin, Etoposide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 987 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Rogers, Arkansas + 16 more
- Conditions
- Hyperinsulinism
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Up to 12 Months
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Thymidine Kinase 2 Deficiency
- Interventions
- doxecitine and doxribtimine
- Drug
- Lead sponsor
- UCB BIOSCIENCES, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- paclitaxel
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2006
- U.S. locations
- 34
- States / cities
- La Jolla, California • San Francisco, California • Wilmington, Delaware + 25 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- gemcitabine hydrochloride, alvocidib, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Gonococcal Infection
- Interventions
- Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090 A26, Neisseria gonorrhoeae strain FA7537
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 36 Years · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- Allopurinol, Keppra, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplant, Filgrastim, antithymocyte globulin
- Drug · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 44 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Light Chain (AL) Amyloidosis
- Interventions
- NXC-201 CAR-T
- Biological
- Lead sponsor
- Nexcella Inc.
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2039
- U.S. locations
- 18
- States / cities
- Berkeley, California • Duarte, California • Los Angeles, California + 14 more
- Conditions
- Solid Tumors and Lymphomas
- Interventions
- Alobresib, Exemestane, Fulvestrant
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Fort Wayne, Indiana • Goshen, Indiana + 1 more
- Conditions
- Asthma
- Interventions
- fluticasone, Standard Asthma Discharge Instructions
- Drug · Other
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 3 Years to 12 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Advanced Solid Tumor Cancer
- Interventions
- X-PACT
- Combination Product
- Lead sponsor
- Immunolight, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Charlotte, North Carolina • Durham, North Carolina + 1 more
- Conditions
- MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
- Interventions
- Glycerol Tributyrate
- Drug
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia